BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $160 | -41.4% | 22,609 | -41.8% | 0.02% | -52.9% |
Q2 2023 | $273 | -99.9% | 38,825 | +42.4% | 0.03% | +3.0% |
Q2 2022 | $288,000 | -1.7% | 27,257 | +51.3% | 0.03% | -5.7% |
Q1 2022 | $293,000 | -23.9% | 18,017 | -32.7% | 0.04% | -23.9% |
Q3 2021 | $385,000 | +296.9% | 26,774 | +32.0% | 0.05% | +206.7% |
Q2 2020 | $97,000 | -2.0% | 20,284 | -58.9% | 0.02% | -21.1% |
Q1 2020 | $99,000 | -18.9% | 49,335 | +207.7% | 0.02% | +11.8% |
Q3 2018 | $122,000 | -15.3% | 16,036 | -38.0% | 0.02% | -37.0% |
Q2 2017 | $144,000 | -57.3% | 25,885 | -35.6% | 0.03% | -65.8% |
Q1 2017 | $337,000 | +524.1% | 40,190 | +110.3% | 0.08% | +426.7% |
Q1 2016 | $54,000 | -74.9% | 19,107 | +32.7% | 0.02% | -80.0% |
Q2 2015 | $215,000 | – | 14,397 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |